Please use this identifier to cite or link to this item:
|Title:||Moving forward with Takeda's live chimeric tetravalent dengue vaccine||Authors:||Wilder-Smith, Annelies||Keywords:||Dengue
|Issue Date:||2017||Source:||Wilder-Smith, A. (2017). Moving forward with Takeda's live chimeric tetravalent dengue vaccine. The Lancet Infectious Diseases, 17(6), 566-568.||Series/Report no.:||The Lancet Infectious Diseases||Abstract:||Several decades of dengue vaccine research have shown how challenging it is to develop a highly efficacious vaccine that protects against all four dengue serotypes (DENV-1–4) for people of all ages. In light of the rapidly rising incidence of dengue virus infection, now estimated to affect about 100 million individuals per year,1 the approval of the first dengue vaccine developed by Sanofi Pasteur (CYD-TDV) was a welcome step forward.2 However, the first vaccine does not present a simple solution.||URI:||https://hdl.handle.net/10356/83617
|ISSN:||1473-3099||DOI:||10.1016/S1473-3099(17)30165-2||Rights:||© 2017 Elsevier Ltd. This is the author created version of a work that has been peer reviewed and accepted for publication by The Lancet Infectious Diseases, Elsevier Ltd. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1016/S1473-3099(17)30165-2].||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||LKCMedicine Journal Articles|
Files in This Item:
|Takeda’s live chimeric tetravalent dengue vaccine- moving forward with a two-dose schedule into Phase 3 trials.pdf||414.52 kB||Adobe PDF|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.